Odyssey Health Inc

For the period ended Apr 30, 2024. Filed Jun 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Apr 30, 2024 · Filed Jun 14, 2024

ODYYStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

	For the Three Months Ended April 30,		For the Nine Months Ended April 30,
	2024	2023	2024	2023
In-process research and development expense	$–	$–	$–	$170,000
Research and development expense	–	35,040	65,766	393,144
Stock-based compensation	51,483	553,964	1,051,671	1,993,631
General and administrative expense	320,888	505,606	1,259,606	2,102,132
Loss from operations	(372,371)	(1,094,610)	(2,377,043)	(4,658,907)
Gain on sale of asset	–	–	16,400,687	–
Loss on investment	(367,929)	–	(1,700,909)	–
Interest expense	(102,227)	(189,415)	(434,689)	(454,907)
Other income (expense), net	186	(79)	9,144	8,402
Net income (loss)	(842,341)	(1,284,104)	11,897,190	(5,105,412)
Deemed dividend	–	–	(63,455)	–
Net income (loss) attributable to common stockholders	$(842,341)	$(1,284,104)	$11,833,735	$(5,105,412)
Basic net income (loss) per share attributable to common stockholders	$(0.01)	$(0.02)	$0.13	$(0.06)
Diluted net income (loss) per share attributable to common stockholders	$(0.01)	$(0.02)	$0.11	$(0.06)
Shares used for basic net income (loss) per share attributable to common stockholders	103,789,222	83,162,747	94,496,866	81,835,188
Shares used for diluted net income (loss) per share attributable to common stockholders	103,789,222	83,162,747	113,895,608	81,835,188

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.